Evolution of the Average Target: Fulcrum Therapeutics, Inc.

Evolution of the Average Target - Fulcrum Therapeutics, Inc.

Evolution of the Target Price: Fulcrum Therapeutics, Inc.

Evolution of the Target Price - Fulcrum Therapeutics, Inc.

Changes in Analyst Recommendations: Fulcrum Therapeutics, Inc.

7926f014e54af52d8540087696a.upFzbYT8TdBBllK3UKNBDz8OqyIxNwlDsZTp4MxafxY._MgmAdu3dZoppRPwPfcAempJ7g9le2dy58O9gvhrTFHg4DUE6rk_ogf6OQ~d692378aa44b4b234c7f41c61cf573bd
06-03 JPMorgan Downgrades Fulcrum Therapeutics to Underweight From Overweight MT
06-02 Top Midday Decliners MT
06-02 Top Premarket Decliners MT
06-02 Piper Sandler Downgrades Fulcrum Therapeutics to Underweight From Overweight, Adjusts PT to $3 From $23 MT
06-02 Stifel Downgrades Fulcrum Therapeutics to Hold From Buy, Adjusts PT to $3 From $25 MT
06-02 Cantor Fitzgerald Downgrades Fulcrum Therapeutics to Neutral From Overweight MT
06-02 HC Wainwright Downgrades Fulcrum Therapeutics to Neutral From Buy, Adjusts PT to $3 From $25 MT
06-02 Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform From Outperform, Adjusts PT to $4 From $24 MT
01-12 JPMorgan Initiates Coverage on Fulcrum Therapeutics With Overweight Rating, $20 Price Target MT
12-08 RBC Raises Price Target on Fulcrum Therapeutics to $10 From $7, Keeps Sector Perform, Speculative Risk MT
11-07 Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) RE
25-07-30 RBC Raises Price Target on Fulcrum Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk MT
25-07-29 HC Wainwright Upgrades Fulcrum Therapeutics to Buy From Neutral, $12 Price Target MT
25-05-23 Fulcrum Therapeutics Shares Rise After Upgrade From Leerink MT
25-05-23 Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4 MT
25-05-15 Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade MT
25-05-15 Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10 MT
24-09-13 HC Wainwright Downgrades Fulcrum Therapeutics to Neutral From Buy, Cuts Price Target to $4 From $17 MT
24-09-13 Top Premarket Decliners MT
24-09-13 RBC Downgrades Fulcrum Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $15; Speculative Risk Kept MT
24-09-12 Stifel Nicolaus Downgrades Fulcrum Therapeutics to Hold From Buy, $3 Price Target MT
24-09-12 Piper Sandler Cuts Price Target on Fulcrum Therapeutics to $6 From $16, Maintains Overweight Rating; Shares Plunge MT
24-09-12 Cantor Fitzgerald Downgrades Fulcrum Therapeutics to Neutral From Overweight MT
24-09-09 BofA Securities Upgrades Fulcrum Therapeutics to Neutral From Underperform, Raises Price Target to $10 From $5 MT
24-09-03 RBC Adjusts Price Target on Fulcrum Therapeutics to $15 From $14, Maintains Outperform, Speculative Risk Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+0.46%
+32.97%
+14.74%
+38.45%
+12.07%
+18.26%
+44.87%
+38.06%
+24.78%
+8.87%
Average +23.35%
Weighted average by Cap. +26.74%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
3.650USD
Average target price
3.667USD
Spread / Average Target
+0.46%
High Price Target
4.000USD
Spread / Highest target
+9.59%
Low Price Target
3.000USD
Spread / Lowest Target
-17.81%

Analyst Consensus Detail

Analyst consensus - Fulcrum Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Fulcrum Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Fulcrum Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. FULC Stock
  4. Consensus Fulcrum Therapeutics, Inc.